

## AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE 2024 SCIENTIFIC CONGRESS & EXPO

# EFFECT OF TROPHECTODERM REBIOPSY ON SERUM B-HUMAN CHORIONIC GONADOTROPIN LEVELS IN PREGNANCIES RESULTING IN LIVE BIRTHS

Rebecca Zhuo, Tamar Alkon-Meadows, Samantha Lauren Estevez, Atoosa Ghofranian, Emily Auran Clarke, Morgan Baird, Joseph A. Lee, Dmitry Gounko, Rachel B. Danis, Alan B. Copperman, Erkan Buyuk

- 1. Reproductive Medicine Associates of New York, New York, NY
- 2. Icahn School of Medicine at Mount Sinai, New York, NY

## **OBJECTIVE:**

Approximately 5 to 7 cells are removed from the trophectoderm (TE) during embryo biopsy for preimplantation genetic testing for an uploidy (PGT-A). Rebiopsy is performed in 1-3% of cases due to inconclusive results. The TE gives rise to the placenta which produces  $\beta$  human chorionic gonadotropin ( $\beta$ -hCG), an important diagnostic and prognostic marker in early pregnancy (1). Whether rebiopsy depletes TE cell count to a degree that could affect  $\beta$ -hCG levels is yet to be established. This study aimed to assess if rebiopsy is associated with lower  $\beta$ -hCG in early pregnancy compared to once-biopsied or untested embryos.

#### **MATERIALS AND METHODS:**

This retrospective study included patients who underwent euploid single frozen embryo transfer (sFET) following rebiopsy and achieved a live birth from 2015 to 2022.Patients were matched by age, body mass index, and anti-Müllerian hormone to those who underwent single-biopsy euploid sFET and untested sFET. Multiple gestations were excluded. The primary outcome was serum  $\beta$ -hCG on days 8-12 after embryo transfer. Secondary outcomes were rates of preterm birth and small for gestational age (SGA) infants. Statistics were performed using chi square, Student's t-test, ANOVA, and Kruskal-Wallis, with p<0.05 as significant.

## **RESULTS:**

308 patients undergoing sFET were included: 44 rebiopsy, 132 single-biopsy, and 132untested. Demographics and cycle characteristics were similar. β-hCG was significantly lower in the rebiopsy group compared to single-biopsy and untested groups on days 9-12 and days 8-9, 11-12, respectively (Table 1). β-hCG was similar between single-biopsy and untested groups. There were no significant differences in rates of preterm birth or SGA among all groups.



Mean β- hCG(mUl/ mL)	Untested (0)	Single- Biopsy(1)	Rebiopsy (2)	p-value0 vs 1	p-value0 vs 2	p-value1 vs 2
Day 8	111.2 + 67.7	96.2 + 45.3	65.4 + 36.9	0.35	0.04*	0.16
Day 9	152.5 + 80.3	149.6 + 67.2	110.4 + 69.0	0.34	0.03*	0.04*
Day 10	285.4 + 210.8	226.7 + 144.8	130.8 + 91.4	0.28	0.06	0.002*
Day 11	443.6 + 230.0	433.6 + 246.0	219.9 + 203.7	0.81	0.007*	0.001*
Day 12	648.3 + 428.0	614.4 + 344.7	398.3 + 241.8	0.68	0.03*	0.02*

### CONCLUSIONS:

 $\beta$ -hCG was significantly lower in patients who underwent sFET with a rebiopsied embryo, yet no differences were observed in preterm birth or SGA.  $\beta$ -hCG was similar between single-biopsy and untested groups, suggesting an impact only when 10 or more TE cells are removed in rebiopsy. Understanding the relationship between rebiopsy and  $\beta$ -hCG can help guide management of these pregnancies as lower levels may not be indicative of poor pregnancy outcomes.

#### **IMPACT STATEMENT:**

Rebiopsy is associated with significantly lower  $\beta$ -hCG in pregnancies resulting in live births. The number of biopsies per embryo is an additional factor to be integrated in developing personalized prognostic information for patients.

#### **REFERENCES:**

1. Homan G, Brown S, Moran J, Homan S, Kerin J. Human chorionic gonadotropin as a predictor of outcome in assisted reproductive technology pregnancies. Fertil Steril. 2000 Feb;73(2):270-4. doi:10.1016/s0015-0282(99)00512-9. PMID: 10685527.